Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
The DOI matches its Crossref record, with a small difference in title or year; 61 of the 61 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy. METHODS: A total of 1050 black patients who had New York Heart Association class III or IV heart failure with dilated ventricles were randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addition to standard therapy for heart failure. The primary end point was a composite score made up of weighted values for death from any cause, a first hospitalization for heart failure, and change in the quality of life. RESULTS: The study was terminated early owing to a significantly higher mortality rate in the placebo group than in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs. 6.2 percent, P=0.02). The mean primary composite score was significantly better in the group given isosorbide dinitrate plus hydralazine than in the placebo group (-0.1+/-1.9 vs. -0.5+/-2.0, P=0.01; range of possible values, -6 to +2), as were its individual components (43 percent reduction in the rate of death from any cause [hazard ratio, 0.57; P=0.01] 33 percent relative reduction in the rate of first hospitalization for heart failure [16.4 percent vs. 22.4 percent, P=0.001], and an improvement in the quality of life [change in score, -5.6+/-20.6 vs. -2.7+/-21.2, with lower scores indicating better quality of life; P=0.02; range of possible values, 0 to 105]). CONCLUSIONS: The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure including neurohormonal blockers is efficacious and increases survival among black patients with advanced heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary outcome was a weighted score, but individual components of the outcome showed a difference favouring H-ISDN for all-cause mortality, first HHF, and change in quality of life score.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [79]
In the citing paper
“Digoxin may reduce the risk of HF hospitalization in patients with HFrEF treated with ACE-Is, irrespective of diabetes status.519”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [519]
Citations
Cites
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress
Cai, H., & Harrison, D. G. (2000) · Circulation Research · doi:10.1161/01.res.87.10.840 · Cited by 3,839
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Self-citationEffect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250502 · Cited by 2,833
Self-citationSuperoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
Gryglewski, R. J., Palmer, R. M. J., & Moncada, S. (1986) · Nature · doi:10.1038/320454a0 · Cited by 2,400
Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
Self-citationEffect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,661
Cited by
Items 601–700 of 1,001
Pharmacological treatments of cardiovascular diseases: Evidence from real-life studies
Salvo, F., Bezin, J., Bosco‐Lévy, P., Létinier, L., Blin, P., Pariente, A., & Moore, N. D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.006 · Cited by 27
Hartog, J., Blokzijl, F., Dijkstra, S., DeJongste, M. J. L., Reneman, M. F., Dieperink, W., van der Horst, I. C. C., Fleer, J., van der Woude, L. H. V., van der Horst, I. C. C., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031738 · Cited by 25
“Both the ideas of the combined primary endpoint and the weighting of the individual components were derived from other studies.(41) 54 55 Assigning different weights to the components was needed for more accurate comparison.”
BackgroundMethodInfluentialRacial and Ethnic Differences in Response to Anticoagulation: A Review of the Literature
Gibson, C. M., & Yuet, W. C. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019894142 · Cited by 25
Joseph, M. S., Palardy, M., & Bhave, N. M. (2020) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2020.01.24 · Cited by 24
“Dialysis staff typically look for peripheral edema and lung rales as signs of volume overload, but the subtler exam findings of jugular venous distension and a third heart sound can be helpful markers as well (Wang et al., 2005).”
BackgroundSane, D. C., Streer, N. P., & Owen, J. D. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01172.x · Cited by 24
“Based on the A-HEFT trial (72) this combination, along with RAS blockade, is especially appealing in patients of African descent with TTP.”
Mixed Race: Understanding Difference in the Genome Era
Phillips, E. M., Odunlami, A. O., & Bonham, V. L. (2007) · Social Forces · doi:10.1093/sf/86.2.795 · Cited by 24
“BiDil, a combination of two generic drugs, Isorsorbide Dinitrate and Hydrazaline, was shown to successfully reduce mortality and hospitalization rates and increase quality of life among hypertensive black patients in the AfricanAmerican Heart Failure Trial (Taylor et al. 2004).”
BackgroundAntioxidant treatment for heart failure: friend or foe?
Thomson, M. J., Frenneaux, M. P., & Kaski, J. C. (2008) · QJM · doi:10.1093/qjmed/hcn160 · Cited by 25
Grigorian-Shamagian, L., González‐Juanatey, J. R., Vázquez, R., Cinca, J., Bayés‐Genís, A., Pascual-Figal, D. A., Fernández-Palomeque, C., Bardají, A., Almendral, J. M., Nieto, V., et al. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.03.006 · Cited by 23
Hoseini, S. G., Heshmat‐Ghahdarijani, K., Khosrawi, S., Garakyaraghi, M., Shafie, D., Mansourian, M., Roohafza, H., Azizi, E., & Sadeghi, M. (2022) · Clinical Cardiology · doi:10.1002/clc.23796 · Cited by 23
“Also, a compound clinical score was calculated at Week 24 for each patient, composed from all‐ cause mortality, any hospitalization for HF exacerbation, and changes in quality of life measured by the Minnesota Living with Heart Failure Questionnaire (MLHFQ).(12) Each component was scored according to Table S1 and the…”
MethodHeart Failure with Preserved Ejection Fraction in Older Adults
Chen, M. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.01.038 · Cited by 27
Neurohormonal control of heart failure
Francis, G. S. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78.s1.13 · Cited by 26
Diagnosis and Management of Acute Heart Failure Syndromes
Gheorghiade, M., Filippatos, G. S., & Felker, G. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00027-5 · Cited by 30
Effect of Melatonin on Heart Failure: Design for a Double-Blinded Randomized Clinical Trial
Sadeghi, M., Khosrawi, S., Heshmat‐Ghahdarijani, K., Gheisari, Y., Roohafza, H., Mansoorian, M., & Hoseini, S. G. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12829 · Cited by 24
Treatment of Systolic and Diastolic Heart Failure in the Elderly
Aronow, W. S. (2005) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2005.07.008 · Cited by 24
Volterrani, M., Hálasz, G., Adamopoulos, S. N., Agostoni, P., Butler, J., Coats, A. J. S., Solal, A. C., Doehner, W., Filippatos, G., Jankowska, E. A., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad400 · Cited by 22
Targets and management of hypertension in heart failure: focusing on the stages of heart failure
Miao, H., Zou, C., Yang, S., Chia, Y. C., Minh, H. V., Sogunuru, G. P., Tay, J. C., Wang, T., Kario, K., & Zhang, Y. (2022) · Journal of Clinical Hypertension · doi:10.1111/jch.14553 · Cited by 24
Artificial intelligence: Applications in cardio-oncology and potential impact on racial disparities
Echefu, G. C., Shah, R., Sanchez, Z., Rickards, J., & Brown, S.-A. N. (2024) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2024.100479 · Cited by 30
Stevenson, W., Yancy, C. W., Mancini, M. E., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Francis, S. A., Ganiats, T. G., Jessup, M. L., et al. (2009) · Cited by 22
Self-citationHeart failure: Definition, classification, and pathophysiology – A mini-review
Adebayo, S. O., Olunuga, T. O., Durodola, A., & Ogah, O. S. (2017) · Nigerian Journal of Cardiology · doi:10.4103/0189-7969.201913 · Cited by 22
Liu, X., Désilles, N., & Lebrun, L. (2020) · European Polymer Journal · doi:10.1016/j.eurpolymj.2020.109846 · Cited by 22
Jackson, J. F., & Kornbluth, A. A. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01371.x · Cited by 22
“, congestive heart failure) (79, 80) differential responses to drug therapy have led to race-based FDA drug approval (81), and have sparked enormous debate based on issues of scientific validity versus racial prejudice in drug development by the pharmaceutical industry (80, 82).”
BackgroundIsosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety
Ferdinand, K. C. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.6.993 · Cited by 22
Self-citationSex differences in response to chronic heart failure therapies
Ghali, J. K., & Lindenfeld, J. M. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.4.555 · Cited by 24
Pleiotropic Effects of Calcium Channel Blockers
Mason, R. P. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0269-4 · Cited by 23
“That trial showed that the addition of isosorbide dinitrate and hydralazine to conventional therapy reduced relative 1-year mortality by 43 % among African American subjects with advanced heart failure [28].”
Dong, L., Fakeye, O. A., Graham, G. N., & Gaskin, D. J. (2017) · Medical Care Research and Review · doi:10.1177/1077558717725884 · Cited by 25
Oxidativer Stress und kardiovaskuläre Erkrankungen
Bassenge, E., Schneider, H. T., & Daiber, A. (2005) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-2005-923325 · Cited by 28
Guidelines for Statistical Analysis Plans
DeMets, D. L., Cook, T. D., & Buhr, K. A. (2017) · JAMA · doi:10.1001/jama.2017.18954 · Cited by 29
Harrison, D. G., & Luther, J. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2930-6.00006-9 · Cited by 21
Tan, N. S., Ali, S. H., Lebovic, G., Mamdani, M., Laupacis, A., & Yan, A. T.-K. (2017) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.117.003753 · Cited by 21
Wang, Y., Nguyen, D. T., Yang, G., Anesi, J., Kelly, J., Chai, Z., Ahmady, F., Charchar, F. J., & Golledge, J. (2021) · Assay and Drug Development Technologies · doi:10.1089/adt.2020.1027 · Cited by 21
“Hydralazine is an antihypertensive drug that is commonly investigated in heart failure, 8 cancer, 9,10 and blood pressure research.”
Hill, L., Baruah, R., Beattie, J. M., Bistola, V., Castiello, T., Čelutkienė, J., Stolfo, G. D., Geller, T. P., Lambrinou, E., Mindham, R., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2973 · Cited by 21
Primary Care Physicians’ Attitudes Regarding Race-Based Therapies
Frank, D., Gallagher, T. H., Sellers, S. L., Cooper, L. A., Price‐Haywood, E. G., Odunlami, A. O., & Bonham, V. L. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-009-1190-7 · Cited by 21
Chang, S., Newton, P. J., Inglis, S. C., Luckett, T., Krum, H., Macdonald, P. S., & Davidson, P. M. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9369-0 · Cited by 21
Traynham, C. J., Roof, S. R., Wang, H., Prosak, R. A., Tang, L., Viatchenko‐Karpinski, S., Ho, H., Racoma, I. O., Catalano, D. J., Huang, X. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052005 · Cited by 23
“Recently, therapies have been developed to target superoxide (O2 ) or nitric oxide (NO) [1].”
BackgroundSchuster, A., Thakur, A., Wang, Z., Borowski, A. G., Thomas, J. D., & Tang, W. H. W. (2012) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2012.08.356 · Cited by 22
“NO-donating drugs have already shown some promising benefits in ambulatory patients with HF and hemodynamic derangements.(21,22) There is also a need to better understand the potential for serial monitoring of postexercise eNO in tracking with another dimension of disease progression.”
Hasenfuss, G. P., Anker, S. D., Bauersachs, J. K., Böhm, M., Hoppe, U. C., Pieske, B. M., von Scheidt, W., & Wachter, R. (2013) · Der Kardiologe · doi:10.1007/s12181-013-0491-6 · Cited by 28
Anand, I. S., Win, S., Rector, T. S., Cohn, J. N., & Taylor, A. L. (2014) · Circulation Heart Failure · doi:10.1161/circheartfailure.114.001360 · Cited by 22
Self-citationChang, K., Beri, N., Nguyen, N. H., Arbit, B., Fox, S., Mojaver, S., Clopton, P., Tam, S. W., Taylor, A. L., Cohn, J. N., et al. (2017) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2017.09.005 · Cited by 21
Self-citationResistant Hypertension Updated Guidelines
Chernova, I., & Krishnan, N. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1209-6 · Cited by 22
A Modern Integration of Palliative Care Into the Management of Heart Failure
Puckett, C., & Goodlin, S. J. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.05.004 · Cited by 21
Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management
Patel, P. H., Nguyen, M., Rodriguez, R., Surani, S., & Udeani, G. (2021) · Cureus · doi:10.7759/cureus.12419 · Cited by 29
“This benefit has been more profound in African-American patients, with severe symptomatic heart failure (NYHA class III or IV), where hydralazine and isosorbide dinitrate combination in addition to ACE inhibitor or ARB and beta-blocker, has been shown to favorably affect myocardial remodeling as well as mortality [31].”
BackgroundThe Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction
Cordwin, D. J., Berei, T. J., & Pogue, K. T. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211042706 · Cited by 21
Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy
Rahamim, E., Nachman, D., Yagel, O., Yarkoni, M., Elbaz‐Greener, G., Amir, O., & Asleh, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194409 · Cited by 24
“The recommendation of combining ACE inhibitors with isosorbide dinitrate and hydralazine is based on the African American Heart Failure Trial (A-HeFT), demonstrating a 4% improved survival and a 33% reduction in first HF hospitalization in HFrEF patients [35].”
MethodInfluentialEthnic and Racial Disparities in Diagnosis, Treatment, and Follow-up Care
PIERCE, R. O. (2007) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/00124635-200700001-00004 · Cited by 21
Ellison, G. T. H., Kaufman, J. S., Head, R. F., Martin, P. A., & Kahn, J. (2008) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2008.290.x · Cited by 21
Hypertension Management in the High Cardiovascular Risk Population
Maraj, I., Makaryus, J. N., Ashkar, A., McFarlane, S. I., & Makaryus, A. N. (2013) · International Journal of Hypertension · doi:10.1155/2013/382802 · Cited by 27
Race, Skin Color and Genetic Ancestry: Implications for Biomedical Research on Health Disparities
Kittles, R. A., Santos, E. R., Oji-Njideka, N. S., & Bonilla, C. (2007) · Californian Journal of Health Promotion · doi:10.32398/cjhp.v5isi.1195 · Cited by 24
“Rather than studying a large heterogeneous population, we examined a specific population” (Taylor et al., 2004).”
BackgroundPharmacological management of hypertension in the elderly and frail populations
Correa, A. A., Rochlani, Y. M., Khan, M. H., & Aronow, W. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1500896 · Cited by 23
“For elderly black patients, a combination of hydralazine and isosorbide dinitrate may be used [98].”
BackgroundTraditional and Novel Approaches to Management of Heart Failure: Successes and Failures
Anand, I. S., & Florea, V. G. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2008.01.001 · Cited by 23
Diuretic resistance in heart failure
Iyengar, S., & Abraham, W. T. (2006) · Current Heart Failure Reports · doi:10.1007/s11897-006-0030-x · Cited by 21
“Recently, the combination of nitrates and hydralazine has emerged as an additive therapy for certain select subgroups of patients with HF [ 5 ].”
BackgroundMiller, E. R., Gallo, P. P., He, W., Kammerman, L. A., Koury, K. J., Maca, J., Jiang, Q., Walton, M. K., Wang, C., Woo, K., et al. (2016) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479016665434 · Cited by 21
“A-HeFT The A-HeFT trial compared isosorbide dinitrate/hydralazine hydrochloride (BiDil) to placebo in African American heart failure patients.(31) The primary endpoint involved a novel composite score algorithm, including all-cause mortality as a component.”
MethodMedical Management of Patients With Heart Failure and Reduced Ejection Fraction
Greenberg, B. (2022) · Korean Circulation Journal · doi:10.4070/kcj.2021.0401 · Cited by 26
Insuficiencia cardiaca. ¿Son diferentes las mujeres?
Leiro, M. G. C., & Martín, M. J. P. (2006) · Revista Española de Cardiología · doi:10.1157/13091374 · Cited by 21
Gill, P. S., Davis, R., Davies, M., Freemantle, N., & Lip, G. Y. H. (2009) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-9-47 · Cited by 20
“[1, 16 ] Finally, HF has a very high mortality, at around 80% in men within six years of diagnosis [17], a prognosis worse than most forms of cancer.”
BackgroundMedication Management of Chronic Heart Failure in Older Adults
Alagiakrishnan, K., Banach, M., Jones, L. G., Ahmed, A., & Aronow, W. S. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0105-9 · Cited by 22
Phillips, R. A., Fonseca, V. A., Katholi, R. E., McGill, J. B., Messerli, F. H., Bell, D. S. H., Raskin, P., Wright, J. T., Iyengar, M. K., Anderson, K. M., et al. (2008) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.00017.x · Cited by 23
Bidil: recontextualizing the race debate
Séguin, B., Hardy, B.-J., SINGER, P. A., & Daar, A. S. (2008) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500489 · Cited by 20
Pattern of Bladder Cancer at University Teaching Hospital, Lusaka, Zambia in the era of HIV Epidemic
Mapulanga, V. (2012) · Medical Journal of Zambia · Cited by 21
Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm
Loudon, B. L., Noordali, H., Gollop, N. D., Frenneaux, M. P., & Madhani, M. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13480 · Cited by 21
“00 01 ) G ra n ge r et al ., 20 03 Va ls ar ta n Va l-H eF T tr ia l (a d de d to A C EIs ) 50 10 1.”
BackgroundInfluentialNyolczas, N., Dékány, M., Muk, B., & Szabo, B. A. (2017) · Advances in experimental medicine and biology · doi:10.1007/5584_2017_112 · Cited by 24
Steven, S., Oelze, M. W., Hausding, M., Roohani, S., Kashani, F., Kröller‐Schön, S., Helmstädter, J., Jansen, T., Baum, C., Iglarz, M., et al. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/7845629 · Cited by 21
“Interestingly, the combination of ISDN and hydralazine has been shown to have strong beneficial and long-lasting hemodynamic effects and has also been demonstrated to improve prognosis of chronic congestive heart failure patients [82, 83], likely because of the improvement of the nitroso-redox balance [84].”
BackgroundAssessing the Impact of Heart Failure Therapeutics on Quality of Life and Functional Capacity
Lewis, E. F. (2013) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-013-0249-2 · Cited by 21
Yancy, C. W. (2008) · Current Hypertension Reports · doi:10.1007/s11906-008-0052-8 · Cited by 20
Self-citationMeschia, J. F. (2009) · Stroke · doi:10.1161/strokeaha.109.562231 · Cited by 21
Iyer, P. S., Dirweesh, A. M., & Zijoo, R. (2017) · Case Reports in Rheumatology · doi:10.1155/2017/5245904 · Cited by 20
“While ANA negative DIL is rare, it has been described [5].”
BackgroundContemporary Approaches to Patients with Heart Failure
Mitter, S. S., & Yancy, C. W. (2017) · Cardiology Clinics · doi:10.1016/j.ccl.2016.12.008 · Cited by 21
Self-citationHydralazine and Nitrates in the Treatment of Heart Failure with Reduced Ejection Fraction
Al‐Mohammad, A. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12459 · Cited by 20
Ghali, J. K., Tam, S. W., Ferdinand, K. C., Lindenfeld, J. M., Sabolinski, M. L., Taylor, A. L., Worcel, M., Curry, C. L., & Cohn, J. N. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707050-00007 · Cited by 20
Self-citationCurrent and Future Considerations in the Use of Mechanical Circulatory Support Devices
Simon, M. A. M., Watson, J. T., Baldwin, J. T., Wagner, W. R., & Borovetz, H. S. (2008) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.9.060906.151856 · Cited by 22
“ACE-inhibitors (lisinopril, enalapril, etc.) Block conversion of angiotensin I to angiotensin II in the RAAS pathway.”
BackgroundInfluentialMechanisms of current therapeutic strategies for heart failure: more questions than answers?
Khan, M. S., Shahid, I., Greene, S. J., Mentz, R. J., DeVore, A. D., & Butler, J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac187 · Cited by 22
Heart failure and diabetes: Clinical significance and epidemiology of this two‐way association
Jerkins, T. W., McGill, J. B., & Bell, D. S. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15062 · Cited by 21
Blood Pressure in Heart Failure
Pfeffer, M. A. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.028 · Cited by 20
Khan, H. M., Kalogeropoulos, A. P., Zannad, F. M., Marti, C. N., Wilson, P. W. F., Georgiopoulou, V. V., Kanaya, A. M., Newman, A. B., Schelbert, E. B., Harris, T. B., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.69 · Cited by 19
Self-citationHydralazine‐Induced Lupus Erythematosis
Handler, J. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00573.x · Cited by 19
Efficacy of beta-blockade after isolated blunt head injury: Does race matter?
Bukur, M., Mosheni, S., Ley, E. J., Salim, A., Margulies, D. R., Talving, P., Δημητριάδης, Δ., & Inaba, K. (2012) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e318241bc5b · Cited by 21
Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy
Butler, J., Januzzi, J. L., & Rosenstock, J. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14042 · Cited by 19
Shahian, D. M., Badhwar, V., O’Brien, S. M., Habib, R., Han, J., McDonald, D. E., Antman, M. S., Higgins, R. S. D., Preventza, O., Estrera, A. L., et al. (2022) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2021.11.067 · Cited by 19
Treatment of Heart Failure in African Americans— A Call to Action
Mitchell, J. E., Ferdinand, K. C., Watson, K. E., Wenger, N. K., Watkins, L. O., Flack, J. M., Gavin, J. R., Reed, J. W., Saunders, E., & Wright, J. T. (2011) · Journal of the National Medical Association · doi:10.1016/s0027-9684(15)30257-1 · Cited by 19
Self-citationHospital compliance with performance measures and 30-day outcomes in patients with heart failure
Schopfer, D. W., Whooley, M. A., & Stamos, T. D. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.04.017 · Cited by 19
Miller, W. L., & Skouri, H. N. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.07.228 · Cited by 20
Prisant, L. M., Thomas, K. L., Lewis, E. F., Huang, Z., Francis, G. S., Weaver, W. D., Pfeffer, M. A., McMurray, J. J. V., Califf, R. M., & Velazquez, E. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.12.050 · Cited by 19
Mentioning race at the beginning of clinical case presentations: a survey of US medical schools
Nawaz, H., & Brett, A. S. (2009) · Medical Education · doi:10.1111/j.1365-2923.2008.03257.x · Cited by 19
Flexible design clinical trial methodology in regulatory applications
Hung, H., Wang, S., & O’Neill, R. T. (2011) · Statistics in Medicine · doi:10.1002/sim.4021 · Cited by 19
“Failure Trial (A-HeFT) [10] elucidate the fact that this inefficient design method may still work on a case-by-case basis in terms of reaching a definitive conclusion for the primary efficacy endpoint on which planning the amount of statistical information was based.”
MethodTreating Heart Failure With Sildenafil
Blum, A. (2009) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2008.00026.x · Cited by 19
Campbell, R. T., Willox, G., Jhund, P. S., Hawkins, N. M., Huang, F., Petrie, M. C., & McMurray, J. J. V. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002842 · Cited by 23
Biglane, J. B., Becnel, M. F., Ventura, H. O., & Krim, S. R. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.08.006 · Cited by 19
Shuey, M. M., Gandelman, J. S., Chung, C. P., Nian, H., Yu, C., Denny, J. C., & Brown, N. J. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-021640 · Cited by 19
Using Measures of Disease Progression to Determine Therapeutic Effect
Granger, C. B., & McMurray, J. J. V. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.050 · Cited by 19
Projecting heart failure into bankruptcy in 2012?
Stevenson, L. W. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.03.020 · Cited by 20
Volterrani, M., Hálasz, G., Adamopoulos, S. N., Agostoni, P., Butler, J., Coats, A. J. S., Solal, A. C., Doehner, W., Filippatos, G., Jankowska, E. A., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3440 · Cited by 24
Ekpo, E., Balla, S., Ngo, S., Witting, C. S., Sarraju, A., Furst, A., & Rodríguez, F. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100743 · Cited by 20
Guidelines for treating heart failure
Kittleson, M. M. (2024) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2024.10.002 · Cited by 19
Abnormal Ca 2+ Cycling in Failing Ventricular Myocytes: Role of NOS1-Mediated Nitroso-Redox Balance
Ziolo, M. T., & Houser, S. R. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.5873 · Cited by 18
“There have been clinical trials (HeFT and A-HeFT) that have examined the effects of isosorbide dinitrate (NO donor) and hydralazine (vasodilator) in HF patients (35, 156).”
Optimal Medical Therapy for Heart Failure
Bukharovich, I. F., & Kukin, M. L. (2006) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2005.11.002 · Cited by 20
Taylor, A. L., Sabolinski, M. L., Tam, S. W., Ziesche, S., Ghali, J. K., Archambault, W. T., Worcel, M., & Cohn, J. N. (2012) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2012.06.526 · Cited by 18
Self-citationDrug Treatment of Chronic Heart Failure in the Elderly
Leibundgut, G., Pfisterer, M. E., & Rocca, H. B. (2007) · Drugs & Aging · doi:10.2165/00002512-200724120-00003 · Cited by 19
Fraccarollo, D., Galuppo, P., Neuser, J., Bauersachs, J. K., & Widder, J. D. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05931 · Cited by 18
Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites
Zamani, P. L., French, B. C., Brandimarto, J., Doulias, P., Javaheri, A., Chirinos, J. A., Margulies, K. B., Townsend, R. R., Sweitzer, N. K., Fang, J. C.-T., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.08.077 · Cited by 18
Brewster, L. M. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12421 · Cited by 19
Juárez, P. D., Tabatabai, M., Valdez, R. B., Hood, D. B., Im, W., Mouton, C. P., Colen, C. G., Al‐Hamdan, M. Z., Matthews-Juarez, P., Lichtveld, M. Y., et al. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17103561 · Cited by 21
Metadata
- Authors
- Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., & Cohn, J. N.
- Affiliations
- University of Minnesota (US)
- United States Department of Veterans Affairs (US)
- The University of Texas Southwestern Medical Center (US)
- Veterans Health Administration (US)
- Xavier University of Louisiana (US)
- Association of Black Cardiologists (US)
- University of North Carolina at Chapel Hill (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-11-11
- Volume
- 351
- Issue
- 20
- Pages
- 2049-2057
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140023412
- Cited by
- 1,773
- References
- 61
- Citations by year
- 2026: 28 · 2025: 30 · 2024: 43 · 2023: 67 · 2022: 68 · 2021: 70 · 2020: 76 · 2019: 53 · 2018: 58 · 2017: 90 · 2016: 78 · 2015: 79 · 2014: 76 · 2013: 78 · 2012: 97
- FWCI
- 84.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- isosorbide dinitrate, hydralazine, advanced heart failure, Black patients, fixed-dose combination, mortality, heart failure hospitalization, quality of life, dilated ventricles
- MeSH terms
- Adult, Aged, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Heart Failure, Humans, Hydralazine, Isosorbide Dinitrate, Male, Middle Aged, Quality of Life, Vasodilator Agents, Survival Analysis, Treatment Outcome, Nitric Oxide Donors, Black People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.